ABSTRACT
The outbreak of the coronavirus disease 2019 (COVID19) pandemic has become the biggest challenge for the whole human community since many years. It seems that the proper identification of all people infected with severe acute respiratory syndrome coronavirus 2 (SARSCoV2) is the best strategy to limit the transmission. However, in a significant proportion of patients, there are no clinical manifestations of the disease, and symptoms may be very mild or atypical. There is a growing body of evidence that digestive manifestations of COVID19 are frequently reported and may precede typical respiratory symptoms. Moreover, SARSCoV2 particles were found in the gastrointestinal epithelial cells, and viral RNA was detected in the feces of patients with COVID19. These data suggest that gastrointestinal symptoms in COVID19 are not accidental findings and they may result from direct digestive involvement. Patients with newonset diarrhea, abdominal pain, nausea, and vomiting without any other evident etiological factors should be tested for SARSCoV2 infection. Gastroenterologists and members of other medical specialties should also remember that the current epidemiological situation has changed diagnostic and therapeutic algorithms in the management of several gastrointestinal and liver disorders. This review article summarizes the currently available data on multiple gastroenterological aspects of COVID19 and provides information on practical recommendations and position statements of the most prominent associations in the field of gastroenterology, which appeared in response to the emergence of the pandemic.
Subject(s)
Betacoronavirus/metabolism , Coronavirus Infections/complications , Digestive System Diseases/virology , Digestive System/virology , Pneumonia, Viral/complications , COVID-19 , Coronavirus/metabolism , Coronavirus Infections/diagnosis , Coronavirus Infections/drug therapy , Coronavirus Infections/therapy , Digestive System/metabolism , Humans , Pandemics , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , SARS-CoV-2 , COVID-19 Drug TreatmentABSTRACT
The novel coronavirus disease is currently causing a major pandemic. It is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the Betacoronavirus genus that also includes the SARS-CoV and Middle East respiratory syndrome coronavirus. While patients typically present with fever and a respiratory illness, some patients also report gastrointestinal symptoms such as diarrhea, vomiting, and abdominal pain. Studies have identified the SARS-CoV-2 RNA in stool specimens of infected patients, and its viral receptor angiotensin converting enzyme 2 was found to be highly expressed in gastrointestinal epithelial cells. These suggest that SARS-CoV-2 can actively infect and replicate in the gastrointestinal tract. This has important implications to the disease management, transmission, and infection control. In this article, we review the important gastrointestinal aspects of the disease.